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Abstract 
Inflammatory cytokines are commonly elevated in acute depression and are associated with 
resistance to monoaminergic treatment. To examine the potential role of cytokines in the 
pathogenesis and treatment of depression, we carried out a systematic review and meta-
analysis of antidepressant activity of anti-cytokine treatment using clinical trials of chronic 
inflammatory conditions where depressive symptoms were measured as a secondary 
outcome. Systematic search of the PubMed, EMBASE, PsycINFO, and Cochrane databases, 
search of reference lists and conference abstracts, followed by study selection process yielded 
20 clinical trials. Random effect meta-analysis of seven randomised controlled trials (RCTs) 
involving 2370 participants showed a significant antidepressant effect of anti-cytokine 
treatment compared with placebo (standardized mean difference (SMD)=0.40, 95% 
confidence interval (CI), 0.22-0.59). Anti-TNF drugs were most commonly studied (five 
RCTs); SMD=0.33 (95% CI; 0.06-0.60). Separate meta-analyses of two RCTs of adjunctive 
treatment with anti-cytokine therapy and eight non-randomised and/or non-placebo studies 
yielded similar small-to-medium effect estimates favouring anti-cytokine therapy; SMD=0.19 
(95% CI, 0.00-0.37) and 0.51 (95% CI, 0.34-0.67), respectively. Adalimumab, etanercept, 
infliximab and tocilizumab all showed statistically significant improvements in depressive 
symptoms. Meta-regression exploring predictors of response found that the antidepressant 
effect was associated with baseline symptom severity (P=0.018) but not with improvement in 
primary physical illness, sex, age or study duration. The findings indicate a potentially causal 
role for cytokines in depression and that cytokine modulators may be novel drugs for 
depression in chronically inflamed subjects. The field now requires RCTs of cytokine 
modulators using depression as the primary outcome in subjects with high inflammation who 
are free of other physical illnesses. 
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Introduction 
The association between the immune system and the brain may offer new mechanistic 
understanding and insights for novel therapies for depression. Cytokine-mediated 
communication between the immune system and the brain has been implicated in the 
pathogenesis of depression.1-3 Major depression is common (one in four) after interferon 
treatment, a potent inducer of cytokines, in patients affected by hepatitis C virus.4 
Experimental immuno-activation in healthy volunteers leads to depressive symptoms and 
reduced cognitive performance.5, 6 Meta-analyses of cross-sectional studies confirm elevated 
levels of circulating inflammatory cytokines in depressed patients,7-10 and longitudinal studies 
have demonstrated that elevated serum cytokine levels precede, so potentially cause 
depressive symptoms.11, 12 A dose-response relationship between serum concentration of 
interleukin 6 (IL-6) in childhood at 9 years and subsequent depressive symptoms in early-
adulthood at 18 years has been reported in the Avon Longitudinal Study of Parents and 
Children (ALSPAC) birth cohort.11  A longitudinal association between circulating 
inflammatory markers and subsequent depressive symptoms has also been reported from the 
Whitehall II cohort.12 Furthermore, activation of the inflammatory system is thought to 
underlie antidepressant resistance highlighting an involvement in treatment response.13, 14 
Therefore, whether targeting inflammation, particularly inflammatory cytokines, could 
provide therapeutic benefit for patients with depression is a key question. 
 
A meta-analysis of randomised controlled trials (RCTs)15 of non-steroidal anti-inflammatory 
drugs (NSAIDs), given as sole treatment or as adjunct to antidepressants, indicates that they 
may be more effective than placebo in treating depression (Cohen’s d=0.27; 95% CI, 0.08-
0.45),16 although there are limitations of individual studies included such as attrition. While 
these results point to an inflammatory component to depression, further examination of the 
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evidence regarding cytokine modulating drugs may help to elucidate the relevance of 
inflammation for pathogenesis and treatment of depression specifically. NSAIDs are broad-
spectrum anti-inflammatory agents that also act on other targets, such as glucocorticoid 
receptors.17 These receptors are, themselves, relevant for depression pathophysiology,18 so 
the extent to which the antidepressant effect of NSAIDs is due solely to anti-inflammatory 
action is unclear. Some NSAIDs such as cyclooxygenase-2 inhibitors increase risk of 
cardiovascular disease,19 a known comorbidity for depression, so their use in depression may 
be problematic. Besides, many trials of anti-inflammatory drugs for depression are based on 
people with chronic physical illness16 but it is unclear whether the improvement in depression 
is due to the improvement in physical illness. 
 
Cytokine modulators, which include monoclonal antibodies and cytokine inhibitors, 
constitute a more pure anti-inflammatory class because they target specific cytokine 
pathways. Recently, a proof-of-concept RCT of infliximab, a tumour necrosis factor alpha 
(TNF-α) specific monoclonal antibody, has reported improvements in patients with treatment 
resistant depression characterized by high inflammation at baseline.20 Supported by a large 
number of RCTs, cytokine modulators are well established treatments for chronic 
inflammatory conditions such as rheumatoid arthritis (RA)21 and psoriasis.22 Many of these 
clinical trials have also reported on secondary psychosocial outcome measures including 
depressive symptoms which could be utilised to address important questions regarding 
potential usefulness of anti-cytokine treatment for depression. In addition to quantifying the 
antidepressant effect of anti-cytokine treatment, examination of the relationship between the 
improvement in depressive symptoms and that in physical symptoms could elucidate the role 
of inflammation in depression specifically. Previous RCTs indicate baseline severity of 
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depression moderates the antidepressant effects of monoaminergic drugs23 and 
psychotherapy24; it not clear whether this is also the case for anti-cytokine treatment. 
 
We report a systematic review and meta-analysis of secondary data from clinical trials of 
anti-cytokine treatment in chronic inflammatory conditions to address the following key 
outstanding questions: (1) does blocking specific inflammatory cytokine pathways lead to 
improvement in depressive symptoms; (2) what is the relationship between the antidepressant 
effect and the improvement in physical illness; (3) is the antidepressant effect related to 
baseline severity of depressive symptoms; (4) is there any sex or age difference of the 
antidepressant effect. Answers to these questions would provide important clues on whether 
inflammatory cytokines play a causal role in depression, and whether cytokine modulators 
may be useful for treating depression. 
 
Materials and Methods 
Search strategy and study selection 
A systematic search of the PubMed, Embase, PsycINFO, and Cochrane databases was carried 
out for all clinical trials of cytokine modulators involving human subjects published in the 
English language until 5th April 2016, where depression or depressive symptoms were 
reported as an outcome. The search terms included indexing terms as well as wildcards to 
maximize return: “(monoclonal antibod* OR cytokine inhibitor OR tocilizumab OR 
infliximab OR adalimumab OR ustekinumab OR etanercept OR dupilumab) AND 
(depression OR depressive symptom)”. We also searched reference lists of retrieved articles 
and conference abstracts, and wrote to key authors in the field for unpublished data. 
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Clinical trials of specific cytokine inhibitors or monoclonal antibodies against specific 
inflammatory cytokines that measured depressive symptoms using a recognised tool were 
included. In order to obtain a comprehensive overview of the literature, we included all 
clinical trial designs, i.e. RCTs, double blind or open label, as well as non-randomised studies 
(analysed separately). Studies that examined cytokine modulators as an adjunct to interferon 
(INF) therapy, used monoclonal antibodies as a method for detecting leukocyte subtypes, or 
examined monoclonal antibodies against targets other than an inflammatory cytokine (e.g. 
vascular growth factor, adhesion molecule) were excluded.25 The literature search and study 
selection were carried out by NK and GMK; any differences were resolved by discussion. 
 
Data extraction and statistical analysis 
Data were extracted from published articles or obtained by directly contacting the authors if 
relevant data were not reported. When authors could not be reached but data were available in 
the paper in graph format (two RCTs),26, 27 values were extracted using software that has been 
shown to be a reliable method of data extraction for meta-analyses.28 RCTs were quality 
assessed using the CONSORT criteria;29 scores reflect the percentage of CONSORT items 
the study adhered to. We aligned depression scales so higher scores reflect higher symptom 
severity by multiplying scores from reversed scales by -1. For studies that included multiple 
intervention arms based on different dosages of the same drug, we pooled means and 
standard deviations of these groups to calculate a single outcome measure. Here, the pooled 
standard deviation (sdpooled) equalled the square root of (sd1^2 * (n1 - 1) + sd2^2 * (n2 - 1)) / 
((n1 - 1) + (n2 - 1)). Effect sizes were calculated as standardised mean difference (SMD) for 
continuous outcomes according to the formula (x̅1 - x̅2) / sdpooled. For binary outcomes odds 
ratios (ORs) were created according to the formula (Outcome1Group1 * Outcome2Group2) / 
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(Outcome2Group1 * Outcome1Group2). Then ORs were transformed to SMD by dividing the 
natural logarithm of the ORs by 1.81.30  
 
Based on study methodology, three types of studies were combined separately using random 
effect meta-analysis: RCTs of anti-cytokine drug vs. placebo; RCTs of adjunctive treatment 
with anti-cytokine therapy (anti-cytokine drug plus active treatment vs. active treatment); and 
other trials (non-randomised and/or non-placebo studies). For RCTs effect estimates were 
calculated as SMD using depression severity scores in treatment and placebo groups at the 
end of trial. SMD is an appropriate measure of effect estimate when studies assess the same 
variable (e.g. depressive symptoms) but measure it in a variety of ways.31 In addition, we 
calculated SMD using change in depression severity score from baseline to end of trial in 
each group to examine the robustness of original results (sensitivity analysis). Sensitivity 
analyses were also carried out after excluding specific RCTs from meta-analysis. For other 
trials, SMD was calculated as difference in depression severity score from baseline to end of 
trial since no control group was present. All studies were weighted using an inverse-variance 
method so studies with larger samples were given higher weight. When possible, pooled 
effect estimates were calculated for specific drugs. Heterogeneity between studies was 
investigated by calculating the Cochrane’s heterogeneity statistic Q and the I2 statistic that 
represents the fraction of variation between studies attributable to heterogeneity.32 
Publication bias was assessed for each group of studies by visual inspection of funnel plots 
including Egger’s test,33 and the trim and fill method.34 We analysed the RCTs of adjunctive 
treatment with anti-cytokine therapy separately because these studies compared combination 
of anti-cytokine drug and a disease-modifying anti-rheumatic drug (DMARD) with DMARD 
alone. One RCT35 administered adalimumab to all participants for four weeks before 
randomising them to placebo or adalimumab for subsequent 52 weeks, so we also included 
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data from the first four weeks in the meta-analysis of “other trials”. Data from two studies36, 
37 that randomised individuals to different dosage regimens of the same drug but lacked a 
placebo group, and a non-randomised study38 were also included in this category.  
 
All secondary analyses were based on placebo-controlled RCTs only as they represent the 
highest quality of scientific evidence of efficacy. Meta-regressions were performed to 
examine the relationship between the effect estimates for depression and (1) the effect 
estimates for primary physical outcome; (2) baseline severity of depressive symptoms; (3) 
sex (percentage of male participants in each sample); and (4) mean age of sample. We 
quantified baseline depression symptom severity in a standardised manner rather than simply 
using mean scores because the studies used different scales to measure depression. We 
identified general population distributions for each scale39-43 that were used to calculate effect 
sizes (SMD) of baseline symptom severity for the sample compared to the general 
population. All analyses were performed in R using the metaphor package for meta-analysis 
and meta-regression;44 analysis codes are available on request.  
 
Results 
The literature search retrieved 350 potentially relevant articles of which 20 studies were 
finally included in the review (see Figure 1 for a PRISMA diagram of literature search). Of 
the included studies, seven were RCTs of anti-cytokine drug vs. placebo, three were RCTs of 
adjunctive treatment with anti-cytokine therapy, and 10 were other study designs such as non-
randomised and/or non-placebo studies (Table 1).   
 
--- Insert Figure 1 here --- 
--- Insert Table 1 here --- 
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Meta-analysis of RCTs of anti-cytokine drug vs. placebo 
Meta-analysis of seven randomised, double-blind, placebo-controlled trials,20, 26, 27, 35, 45-47 
involving 1309 subjects treated with anti-cytokine drugs and 1061 subjects treated with 
placebo, showed significant improvement in depressive symptoms with anti-cytokine 
treatment compared to placebo; SMD=0.40 (95% confidence interval (CI), 0.22-0.59) (Figure 
2a). There was evidence of significant heterogeneity among studies (P<0.001; I2 =73%). 
Anti-TNF drugs were most commonly studied (five RCTs),20, 26, 27, 35, 46 which as a group 
showed significant antidepressant effect; SMD=0.33; 95% CI, 0.06-0.60 (Figure 3). There 
was also evidence of significant heterogeneity among these studies (P=0.02; I2 =75%). 
Regarding specific drugs, based on two trials each, the effect estimate for adalimumab35, 46 
(SMD=0.39; 95% CI, 0.05-0.72) and that for etanercept26, 27 (SMD=0.45; 95% CI, 0.07-0.83) 
were similar (Figure 2a). There was no evidence of significant heterogeneity between the 
adalimumab trials (P =0.134; I2=55%) but there was evidence of heterogeneity among the 
etanercept trials (P =0.05, I2 =73%).  
 
Sensitivity analysis of seven RCTs,20, 26, 27, 35, 45-47 of anti-cytokine drugs vs. placebo based on 
change in depression severity scores from baseline to end of trial yielded very similar results 
to that of the original analysis; SMD=0.37 (95% CI; 0.18-0.57) (see online supplementary 
Figure 1). However, evidence for heterogeneity remained (P<0.001; I2 =76%). 
 
--- Insert Figure 2 here --- 
--- Insert Figure 3 here --- 
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Meta-analysis of RCTs of adjunctive treatment with anti-cytokine therapy 
Of three trials48-50 that used anti-cytokine drugs as adjunctive treatment, two provided enough 
data for meta-analysis (Figure 2b).49, 50 Both of these studies compared combination of 
etanercept and a DMARD (n=544) with DMARD alone (n=405). Meta-analysis showed a 
small effect of etanercept plus DMARD on depressive symptoms compared to DMARD 
alone (SMD=0.19; 95%, CI, 0.00-0.37). There was no evidence of heterogeneity between 
studies (P=0.158; I2=49%).  
 
Meta-analysis of other trials 
Out of 10 non-randomised and/or non-placebo studies,36-38, 51-57 eight provided enough data 
for meta-analysis involving 1744 patients with data at baseline and follow-up (Figure 2c).35, 
36, 38, 51-55 Meta-analysis of these studies suggested significant improvement in depressive 
symptoms following anti-cytokine treatment (SMD=0.51; 95% CI, 0.34-0.67). There was 
evidence of significant heterogeneity among these studies (P < 0.001; I2 =73%). Anti-TNF 
drugs were most commonly studied (six studies), which as a group showed significant anti-
depressant effect (SMD=0.58; 95% CI, 0.39-0.77) (see online supplementary Figure 2). 
However, there was evidence for significant heterogeneity among these studies (P=0.002; I2 
=67%). Regarding specific drugs, adalimumab, infliximab and tocilizumab all showed 
statistically significant improvements in depressive symptoms. Meta-analytic effect estimates 
for adalimumab: SMD=0.67 (95% CI, 0.47-0.87); infliximab: SMD=0.66 (95% CI, 0.14-
1.18); and tocilizumab: SMD=0.31 (95% CI, 0.20-0.42). There was no evidence of 
significant heterogeneity in any of these meta-analyses (all P>0.05).  
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Association with improvement in physical illness 
Meta regression of six RCTs26, 27, 35, 45-47 found no evidence for an association between 
improvement in depressive symptoms and that in primary physical illness outcome measure 
at the end of trial (slope=0.37; SE=0.28; P =0.182) (Figure 4). The study by Raison et al. was 
excluded from this analysis because in this trial depression was the primary outcome so no 
physical illness was studied.20 
 
--- Insert Figure 4 here --- 
 
Association with depression symptom severity at baseline 
Meta-regression of seven RCTs20, 26, 27, 35, 45-47  showed an association between antidepressant 
effect of anti-cytokine treatment and baseline severity of depressive symptoms (slope=-0.12; 
SE=0.05; P =0.018). However, the association became non-significant after excluding the 
RCT by Raison et al.20 (slope=-0.05; SE=0.12; P =0.662). We explored the association by 
excluding the RCT by Raison et al.20 because baseline depression severity was much higher 
in this study (SMD of baseline depression 6.36) compared with the other RCTs (0.08-1.91).  
 
Association with sex and age 
There was no strong evidence for a sex difference in the antidepressant effect of anti-cytokine 
treatment as the association between improvements in depressive symptoms and the 
percentage of male subjects in the sample, based on meta-regression of seven RCTs,20, 26, 27, 35, 
45-47 did not reach significance (slope=1.29; SE=0.66; P =0.051). Re-analysis after excluding 
the study by Raison et al.,20 an outlier in which only 33% of subjects were male, attenuated 
the association further (slope=0.66; SE=0.71; P=0.355). Similarly there was no association 
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between SMD for depressive symptoms and mean age of sample (slope=0.008; SE=0.028; 
P=0.788). 
 
Association with study duration 
Duration of follow-up in the RCTs of anti-cytokine drug vs. placebo was similar (12-16 
weeks) except the study by Loftus et al (Table 1). Meta-regression of seven RCTs20, 26, 27, 35, 
45-47  showed no association between the antidepressant effect of anti-cytokine treatment and 
study duration (slope=-0.004; SE=0.007; P=0.52).  
 
Sensitivity analyses 
Sensitivity analysis of RCTs20, 35, 45-47 excluding two studies by Tyring et al26, 27 from which 
data were extracted using software did not change results substantially; SMD=0.37 (95% CI; 
0.11-0.63) (see online supplementary Figure 3). However, evidence for significant 
heterogeneity remained (P=0.003; I2 =79%). Unlike the other RCTs, the trial by Raison et 
al20 was based on cases of treatment resistant depression without any significant physical 
comorbidity. Meta-analysis of RCTs26, 27, 35, 45-47 excluding this trial yielded a slightly larger 
effect estimate; SMD=0.46 (95% CI; 0.30-0.61) (see online supplementary Figure 4). 
However, there was evidence for significant heterogeneity among these studies (P=0.016; I2 
=61%). The RCT by Loftus et al35 was an outlier in terms of follow-up length (see Table 1). 
Meta-analysis excluding this RCT20, 26, 27, 45-47 did not alter results greatly; SMD=0.43 (95% 
CI; 0.21-0.65) (see online supplementary Figure 5). However, evidence for significant 
heterogeneity remained (P=0.002; I2 =76%). 
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Assessment of publication bias 
Visual inspection of funnel plot of effect estimates from seven RCTs suggested that there was 
no evidence of publication bias (see online supplementary Figure 6), which was in line with a 
non-significant Egger’s test for funnel plot asymmetry (P>0.05). Similarly, trim and fill 
analyses did not show any evidence of funnel plot asymmetry for RCTs.  There were too few 
studies to allow assessment of publication bias among RCTs of adjunctive treatment with 
anti-cytokine therapy. For the other trials (non-randomised, non-placebo) Egger’s test for 
funnel plot asymmetry (P>0.05) and visual inspection of the funnel plot did not suggest any 
evidence for publication bias (see online supplementary Figure 7). However, the trim and fill 
method indicated presence of funnel plot asymmetry, and that additional four studies would 
be needed to reach symmetry leading to slight attenuation of effect size (trim and fill SMD = 
0.36; 95% CI, 0.18-0.55). It is known that the trim and fill method can underestimate effect 
estimates when there is significant heterogeneity among studies;58 indeed, after restricting the 
analysis to anti-TNF studies heterogeneity decreased and there was no longer any evidence of 
funnel plot asymmetry (P=0.50).  
 
Discussion 
Findings from this large systematic review of 20 studies including meta-analyses of 16 
studies totalling 5,063 participants indicate that anti-cytokine treatment improves depressive 
symptoms. We observed significant results favouring cytokine modulators over respective 
control groups with effect estimates of 0.40 for RCTs of anti-cytokine treatment vs. placebo, 
0.19 for RCTs of adjunctive treatment with anti-cytokine therapy, and 0.51 for other (non-
randomised and/or non-placebo) studies. Regarding predictors of response, additional 
analyses based on RCTs indicated that the antidepressant effect was associated with severity 
of depressive symptoms at baseline, but not with improvement in physical illness (primary 
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outcome under investigation in all but one RCT), sex and age of participants, or study 
duration. Sensitivity analyses using a different method to calculate SMD or exclusion of 
specific RCTs did not alter results substantially suggesting that the findings are robust. The 
results provide important clues regarding the role of inflammatory cytokines in depression 
and the potential for cytokine modulators as treatments for depression. Anti-cytokine drugs 
seem to offer treatment effects in the range of small to moderate effect sizes which is 
comparable to estimates observed for common antidepressants.23 The results are in line with a 
previous meta-analysis of NSAIDs which included three RCTs of cytokine inhibitors.16 The 
results are also consistent with a recent meta-analysis of anti-TNF treatment in people with 
chronic physical illness that reported improvements in depression and anxiety symptoms.59 
However, based on a meta-analysis of seven RCTs the current study provides a robust, 
statistically significant effect estimate favouring anti-cytokine treatment for depression. In 
addition to the randomised, double-blind, placebo-controlled clinical trials (gold standard), 
we have examined RCTs of adjunctive treatment with anti-cytokine therapy, and non-
randomised studies offering a comprehensive update of the literature.   
 
Studies included in this review except one by Raison et al20 report continuous measures of 
depression, i.e. symptom severity scores, not a categorical diagnosis of depression. To 
calculate effect size we have used depression severity scores for treatment and placebo 
groups at the end of trial for all RCTs including one by Raison et al. We also used change in 
depression scores from baseline to end of trial. The lack of an association between the 
improvement in depressive symptoms and that in primary physical illness points to a causal 
role for inflammatory cytokines in depression, suggesting that the mood improvement is not 
simply an artefact of feeling physically better after anti-cytokine treatment. Examination of 
the time course of effect in individual studies may provide some clues regarding the 
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underlying mechanism of antidepressant effect of anti-cytokine treatment. The RCT by 
Tyring et al.27 reported scores for fatigue and depression during the course of 12-week 
treatment with etanercept vs. placebo for psoriasis. Compared with placebo, etanercept led to 
improvements in fatigue by two weeks into the study and in depressive symptoms by week 
four. In this study improvement in depressive symptoms was associated with improvement in 
fatigue but not (strongly) with improvement in psoriasis, which is in line with our meta-
regression finding. Neurovegetative symptoms such as fatigue which develop rapidly 
following immune activation in humans are attributed to actions of inflammatory cytokines 
on the brain.60, 61 Therefore, it is possible that the antidepressant effect of anti-cytokine 
treatment is mediated by improvements in cytokine-induced neurovegetative symptoms. This 
hypothesis needs testing in future studies.  
 
In future, RCTs of anti-cytokine treatment using depression as the primary outcome in 
subjects with high inflammation who are free of other physical illnesses are needed. While 
further studies are currently underway (e.g. NCT02363738 and NCT02473289), results from 
the RCT by Raison et al. included in this meta-analysis showed beneficial effects of 
infliximab for treatment resistant depression (TRD) cases only in those with elevated serum 
CRP levels at baseline.20 TRD cases with elevated inflammatory marker levels may be ideal 
candidates for RCTs of cytokine modulators for a number of reasons. About a third of all 
depressed patients are antidepressant resistant62 and about a third of all depressed patients 
have elevated serum CRP (>3mg/L).63 This may not be a coincidence. Indeed, activation of 
the inflammatory system as reflected by elevated serum inflammatory marker concentrations 
predicts poor antidepressant response,13, 14 and treatment resistant patients continue to show 
elevated cytokine levels.64, 65 Inflammation and consequent activation of the tryptophan 
metabolising enzyme indoleamine 2,3-dioxygenase (IDO) is thought to underlie persistent 
17 
 
symptoms despite antidepressant therapy in depressed patients who are ‘inflamed’.66 
Inflammatory cytokines such as interferon-γ, TNF-α and IL-6 can induce IDO.67, 68 In mice, 
blocking TNF-α with etanercept67 or IL-6 with a monoclonal antibody69 have been reported 
to prevent depression-like behaviour following exposures to an inflammatory stimulus or 
stress. Therefore, cytokine modulating therapy is likely to be beneficial for a subset of 
depressed patients, specifically those with evidence of inflammation.  
 
Regarding specific types of studies, meta-analysis of two RCTs of anti-cytokine drugs as 
adjuncts to DMARD treatment showed a smaller effect size than that of the placebo-
controlled randomised trials, which might be due to potential antidepressant effects of drugs 
used as comparison treatment. On the other hand, the pooled effect size for the non-
randomised and/or non-placebo studies was larger than that for RCTs probably because of the 
lack of a comparison group to account for placebo effect. The association between baseline 
severity of depressive symptoms and response to anti-cytokine treatment was markedly 
reduced after excluding an outlier although an association between initial severity and anti-
depressant response is well known.23 This is possibly because depression severity was 
relatively low in all of the RCTs except the one by Raison et al. which included cases of 
TRD.20 It is well known that baseline symptom severity is positively correlated with 
antidepressant treatment effect, so demonstration of a beneficial effect of anti-cytokine 
treatment in samples with relatively low depression scores indicates strong anti-depressant 
properties of these drugs. There was no evidence for an association between antidepressant 
effect of cytokine modulators and sex or age of participants. Similar to depression, 
autoimmune chronic inflammatory conditions such as RA are more common in women than 
men (3:1),70 but sex does not influence response to anti-TNF therapy in patients with 
established RA71 which is in line with our findings. A possible explanation for the lack of an 
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association with age could be limited variability in age among the included studies (<10 
years).  
 
Strengths of the systematic review presented here include a relatively large number of studies 
including RCTs which were quality assessed. The literature search was comprehensive, as 
supported by a lack of evidence for publication bias for most analyses. Inclusion of different 
trial methodologies allowed meta-analyses of two types of RCTs and non-randomised 
studies. The focus on a specific type of anti-inflammatory drug (i.e. cytokine modulators) 
helped to demonstrate the relevance of inflammation, particularly inflammatory cytokines, 
for the pathogenesis and treatment of depression. A potential limitation is the use of data 
extracted from published graphs due to lack of response from authors of two studies.26, 27 
However, the software used to extract data has been reported to be a reliable method for data 
extraction for meta-analysis,28 so any variation from original data would be too small to have 
any meaningful impact on the pooled effect estimate. Because a physical illness was the 
primary outcome in all but one studies included in this review, we were not able to comment 
on potential side effects of cytokine-modulating treatment in depressed individuals 
specifically. Administration of monoclonal antibodies carries the risk of immune reactions 
such as acute anaphylaxis as well as various target-specific adverse effects including 
increased risk of infections, cancer and autoimmune disease.72 Infliximab and placebo groups 
in the study by Raison et al. were similar in terms of adverse events (except increased urinary 
leukocyte esterase in the placebo group) and no serious side effects were observed in either 
group.20 Nevertheless, further studies regarding safety and tolerability of cytokine modulators 
in depressed individuals are needed. There was evidence for significant heterogeneity in the 
meta-analysis of RCTs and that of other trials. Heterogeneity is likely to be driven by 
heterogeneity of effect size because all studies included in these analyses except one showed 
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effect in the same direction, i.e. anti-cytokine treatment improves depressive symptoms (see 
Figures 2a, 2c). Heterogeneity was reduced when studies were grouped by specific 
monoclonal antibodies. For example, there was no evidence of heterogeneity among studies 
of adalimumab, infliximab and tocilizumab. However, sensitivity analyses after excluding 
specific RCTs did not reduce heterogeneity significantly.  
 
In conclusion, this systematic review and meta-analysis provides an up-to-date summary of 
the existing literature on antidepressant effect of anti-cytokine treatment. The findings show 
robust improvements in depressive symptoms after anti-cytokine therapy (monoclonal 
antibody or cytokine inhibitor) with a small-to-moderate size effect. These results suggest 
inflammatory cytokines may play a key role in the pathogenesis of depression and that anti-
cytokine drugs may be effective for some patients with depression, particularly treatment 
resistant cases characterised by increased inflammation. The field now needs RCTs of anti-
cytokine treatment using such patients, which would pave the way for novel, effective and 
personalised treatment for depression and could reduce the burden presented by such a 
serious and multifactorial illness. 
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Figure Legends 
Figure 1: PRISMA Flow Diagram of Study Selection for Systematic Review  
Figure 2: Meta-analysis of Antidepressant Activity of Anti-Cytokine Treatment 
Figure 3: Antidepressant Activity of Anti-TNF Treatment: Meta-analysis of RCTs  
Figure 4: Meta-regression of the Association between Antidepressant Effects and 
Improvements in Physical Illness 
Footnote: P-value for meta-regression slope indicates no statistically significant association between 
antidepressant effect of anti-cytokine treatment and improvement in physical illness. The Figure 
shows that the antidepressant effect does not change significantly (i.e. increase or decrease) across the 
range of effect estimates for physical illness. 
 
Online Supplementary Figure 1: Meta-analysis of RCTs Using Change in Depression 
Score from Baseline to End of Trial 
Online Supplementary Figure 2: Meta-analysis of non-randomised and/or non-placebo 
studies of anti-TNF treatment 
Online Supplementary Figure 3: Meta-analysis of RCTs after excluding two studies 
(Tyring 2006 and Tyring 2013) from which data were extracted using software  
Online Supplementary Figure 4: Meta-analysis of RCTs after excluding Raison et al. 
Online Supplementary Figure 5: Meta-analysis of RCTs after excluding Loftus et al. 
Online Supplementary Figure 6: Funnel Plot of RCTs of Anti-cytokine Drug vs. Placebo 
Online Supplementary Figure 7: Funnel Plot of Non-randomized and/or Non-placebo 
Studies 
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Table 1: Clinical Trials Included in the Systematic Review of Antidepressant Activity of Anti-Cytokine Treatment 
Study Design Drug (n) 
Placebo/ 
comparison 
group (n) 
Main 
Outcome 
Drug 
Target Dosage 
Study 
Duration 
Assessment 
of 
Depressive 
Symptoms† 
Change in mean 
depression score from 
baseline‡ CONSORT 
Score (%) 
         
Treatment 
group 
Placebo/ 
comparison 
group  
RCTs of anti-cytokine drug vs. placebo 
Tyring et al. 
(2006)27 
Double-
blind 
RCT 
Etanercept 
(305) 
Placebo (292) Psoriasis TNF-α  50mg 
twice 
weekly 
12 weeks BDI  -3.9 -2.1 94% 
Loftus et al. 
(2008)35 
[weeks  
4-56] 
Double-
blind 
RCT 
Adalimumab 
(324) 
Placebo (168) Crohn’s 
Disease 
TNF-α  40mg 
weekly or 
every other 
week 
52 weeks ZDS -1.1 +1.8 53% 
Langley et 
al. (2010)47 
Double-
blind 
RCT 
Ustekinuma
b (800) 
Placebo (398) 
 
Psoriasis IL-12, 23  45/90mg at 
weeks 0,4; 
then every 
12 weeks  
12 weeks HADS-D -1.9 +0.2 52% 
Menter et 
al. (2010)46 
Double-
blind 
RCT 
Adalimumab 
(44) 
Placebo (52) Psoriasis TNF-α  40mg 
every other 
week 
12 weeks ZDS -6.7 -1.6 56% 
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Tyring et al. 
(2013)26 
Double-
blind 
RCT 
Etanercept 
(59) 
Placebo (62) Psoriasis TNF-α  50mg 
twice 
weekly 
12 weeks PROMIS 
depression 
score 
-5.5 -2.7 * 
Raison et al. 
(2013)20 
Double-
blind 
RCT 
Infliximab 
(27) 
Placebo (28) Treatment-
resistant 
depression 
TNF-α  5mg/kg at 
weeks 0,2 
and 6 
12 weeks HAM-D -7.5 -9.6 91% 
Simpson et 
al. (2015)45 
Double-
blind 
RCT 
Dupilumab 
(318) 
Placebo (61) Atopic 
Dermatitis 
IL-4R-α  Variable 
(100 to 
600mgs 
every one 
to four 
weeks) 
16 weeks HADS -4.2 +0.1 * 
RCTs of anti-cytokine drugs as adjuncts to an active treatment 
Kekow et 
al. (2010)50 
Double-
blind 
RCT 
Etanercept + 
DMARD 
(265) 
DMARD  
(263) 
Rheumatoi
d arthritis 
TNF-α  50mg 
weekly 
52 weeks HADS-D -2.4 -2.0 48% 
Bae et al. 
(2013)48 
Randomi
sed open-
label 
Etanercept + 
DMARD 
(192) 
DMARD 
(100) 
Rheumatoi
d arthritis 
TNF-α  25mg 
twice 
weekly 
16 weeks HADS-D -2.2 -1.3 63% 
Machado et 
al. (2014)49 
Randomi
sed open-
label 
Etanercept + 
DMARD 
(279) 
DMARD 
(142) 
Rheumatoi
d arthritis 
TNF-α  50 weekly 24 weeks HADS-D -2.8 -1.9 77% 
Non-randomised and/or non-placebo trials 
Minderhoud Single- Infliximab - Crohn’s TNF-α  5mg/kg at 4 weeks CES-D -5.7 - - 
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et al. 
(2007)38 
blind (14) Disease baseline 
Loftus et al. 
(2008)35 
[weeks 0-4] 
Open-
label 
Adalimumab 
(499) 
- Crohn’s 
Disease 
TNF-α  80mg at 
baseline; 
40mg at 
week 2 
4 weeks ZDS -9.1 - - 
Gelfand et 
al. (2008)56 
Open-
label 
Etanercept 
(2546) 
- Psoriasis TNF-α  50mg 
twice 
weekly 
12 weeks BDI Not reported - - 
Dauden et 
al. (2009)37 
Randomi
sed (to 
dosage 
regimen), 
open-
label 
Etanercept 
(703) 
- Psoriasis TNF-α  25 or 
50mg 
twice 
weekly 
54 weeks HADS-D -1.6 - - 
Guh et al. 
(2010)51 
Open-
label 
Adalimumab 
(174) 
- Psoriasis TNF-α  80mg at 
baseline; 
40mg 
every other 
week 
24 weeks BDI -4.4 - - 
Ertenli et al. 
(2012)53 
Open-
label 
Infliximab 
(16) 
- Ankylosin
g 
spondylitis 
TNF-α  5mg/kg at 
weeks 0, 2 
and 6 
6 weeks HADS-D -3.0 - - 
Gniadecki 
et al. 
Randomi
sed (to 
Etanercept 
(752) 
- Psoriasis 
and 
TNF-α  50mg 
weekly; 
12 weeks HADS-D -1.5 - - 
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(2012)36 dosage 
regimen) 
double-
blind 
psoriatic 
arthritis 
50mg 
twice 
weekly 
Bhutani et 
al. (2013)52 
Open-
label 
Adalimumab 
(32) 
- Psoriasis TNF-α  80 to 40mg 
every other 
week 
24 weeks PGWB 
depression  
-1.9 - - 
Eisenberg et 
al. (2013)57 
Open-
label 
Eisenberg 
(9) 
 
- Complex 
regional 
pain 
syndrome 
type 1 
TNF-α  40mg 
twice 
every other 
week 
4 weeks BDI Not reported - - 
Traki et al. 
(2013)54 
Open-
label 
Tocilizumab 
(26) 
- Rheumatoi
d arthritis 
IL-6R  8mg/kg 
monthly 
26 weeks HADS-D -1.0 - - 
Gossec et 
al. (2015)55 
Open-
label 
Tocilizumab 
(610) 
- Rheumatoi
d arthritis 
IL-6R  - - HADS-D -1.3 - - 
 
Note: † BDI = Beck’s Depression Inventory, CES-D = Center for Epidemiological Studies Depression Scale, HAM-D = Hamilton Depression Rating Scale, HADS(-D) = 
Hospital Anxiety and Depression Scale (Depression), PGWB depression = Psychological General Well-Being depression, ZDS = Zung Depression Inventory; * could not 
assess fully because articles published as a letter or as a conference abstract (data from Tyring et al was extracted using software and from Simpson et al by contacting 
authors directly); ‡ (-)ve = decrease in depression score from baseline, (+)ve= increase in depression score from baseline 
